» Articles » PMID: 35440019

OLA1 Promotes Colorectal Cancer Tumorigenesis by Activation of HIF1α/CA9 Axis

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2022 Apr 20
PMID 35440019
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Obg-like ATPase 1 (OLA1) is a highly conserved GTPase, which was over expressed in a variety of malignant tumors, but its role in colorectal cancer (CRC) was poorly studied.

Patients And Methods: Three public CRC gene databases were applied for OLA1 mRNA expression detection. The clinical data of 111 CRC patients were retrospectively collected from the Second Affiliated Hospital of Zhejiang University (SAHZU) for OLA1 protein expression and Kaplan-Meier Survival analysis. OLA1 stably knocked out CRC cell lines were conducted by CRISPR-Cas9 for experiments in vitro and in vivo.

Results: OLA1 was highly expressed in 84% CRC compared to matched surrounding tissues. Patients with OLA1 high expression had a significantly lower 5-year survival rate (47%) than those with OLA1 low expression (75%). OLA1 high expression was an independent factor of poor prognosis in CRC patients. OLA1-KO CRC cell lines showed lower ability of growth and tumorigenesis in vitro and in vivo. By mRNA sequence analysis, we found 113 differential express genes in OLA1-KO cell lines, of which 63 were hypoxic related. HIF1α was a key molecule in hypoxic regulation. Further molecular mechanisms showed HIF1α /CA9 mRNA and/or protein levels were heavily downregulated in OLA1-KO cell lines, which could explain the impaired tumorigenesis. According to previous studies, HIF1α was a downstream gene of GSK3β, we verified GSK3β was over-activated in OLA1-KO cell lines.

Conclusion: OLA1 was a new gene that was associated with carcinogenesis and poor outcomes in CRC by activation of HIF1α/CA9 axis, which may be interpreted by GSK3β.

Citing Articles

Aged gut microbiota promotes arrhythmia susceptibility via oxidative stress.

Fu Z, Ying Y, Wang R, Wang Y iScience. 2024; 27(10):110888.

PMID: 39381749 PMC: 11460473. DOI: 10.1016/j.isci.2024.110888.


Identification and development of Tetra-ARMS PCR-based screening test for a genetic variant of OLA1 (Tyr254Cys) in the human failing heart.

Dubey P, Dubey S, Singh S, Bhat P, Pogwizd S, Krishnamurthy P PLoS One. 2024; 19(6):e0293105.

PMID: 38889130 PMC: 11185490. DOI: 10.1371/journal.pone.0293105.


Obg-like ATPase 1 exacerbated gemcitabine drug resistance of pancreatic cancer.

Liu J, Huang J, Lu J, Ouyang R, Xu W, Zhang J iScience. 2024; 27(6):110027.

PMID: 38883822 PMC: 11177196. DOI: 10.1016/j.isci.2024.110027.


Ten Years of CRISPRing Cancers In Vitro.

Capoferri D, Filiberti S, Faletti J, Tavani C, Ronca R Cancers (Basel). 2022; 14(23).

PMID: 36497228 PMC: 9738354. DOI: 10.3390/cancers14235746.


Association of Common Variants in Gene with Preclinical Atherosclerosis.

Lin T, Chou C, Hsieh C, Wu Y, Chen Y, Wu T Int J Mol Sci. 2022; 23(19).

PMID: 36232807 PMC: 9569939. DOI: 10.3390/ijms231911511.


References
1.
Narasimhan G, Henderson J, Luong H, Rajasekaran N, Qin G, Zhang J . OBG-like ATPase 1 inhibition attenuates angiotensin II-induced hypertrophic response in human ventricular myocytes via GSK-3beta/beta-catenin signalling. Clin Exp Pharmacol Physiol. 2019; 46(8):743-751. PMC: 6650359. DOI: 10.1111/1440-1681.13101. View

2.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

3.
Bai L, Yu Z, Zhang J, Yuan S, Liao C, Jeyabal P . OLA1 contributes to epithelial-mesenchymal transition in lung cancer by modulating the GSK3β/snail/E-cadherin signaling. Oncotarget. 2016; 7(9):10402-13. PMC: 4891128. DOI: 10.18632/oncotarget.7224. View

4.
Smeby J, Sveen A, Merok M, Danielsen S, Eilertsen I, Guren M . CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann Oncol. 2018; 29(5):1227-1234. PMC: 5961317. DOI: 10.1093/annonc/mdy085. View

5.
McIntyre A, Patiar S, Wigfield S, Li J, Ledaki I, Turley H . Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res. 2012; 18(11):3100-11. PMC: 3367109. DOI: 10.1158/1078-0432.CCR-11-1877. View